GENERAL DISCUSSION 197 8 39. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 2004;44(5):472-9. 40. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094108. 41. Leon-Castillo A, Horeweg N, Peters EEM, Rutten T, Ter Haar N, Smit V, et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol. 2022;164(3):577-86. 42. Köbel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, et al. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. Int J Gynecol Pathol. 2017;36(6):555-61. 43. Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF, et al. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol. 2012;120(6):1371-81. 44. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(5):459-76.e10. 45. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(2):170-99. 46. Sozzi G, Fanfani F, Berretta R, Capozzi VA, Uccella S, Buono N, et al. Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study - a multicentric analysis of predictors of failed mapping. Int J Gynecol Cancer. 2020;30(11):1713-8. 47. Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, et al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017;146(2):405-15. 48. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094-108. 49. Schmid S, Hsu IC, Hu JM, Sherman AE, Osann K, Kapp DS, et al. Adjuvant radiation therapy in stage III nodepositive uterine cancer. Gynecol Oncol. 2009;115(2):239-43. 50. Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR. The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecol Oncol. 2016;141(3):434-9. 51. Wong AT, Rineer J, Lee YC, Schwartz D, Safdieh J, Weiner J, et al. Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma. Gynecol Oncol. 2016;142(3):5149. 52. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. 53. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019;380(24):2317-26. 54. van Weelden WJ, Reijnen C, Eggink FA, Boll D, Ottevanger PB, van den Berg HA, et al. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study. Eur J Cancer. 2020;133:104-11. 55. van Weelden WJ, Reijnen C, Küsters-Vandevelde HVN, Bulten J, Bult P, Leung S, et al. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Hum Pathol. 2021;109:80-91. 56. Perrone E, Capasso I, De Felice F, Giannarelli D, Dinoi G, Petrecca A, et al. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. Eur J Cancer. 2023;186:98112. 57. Jamieson A, Huvila J, Chiu D, Thompson EF, Scott S, Salvador S, et al. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Modern Pathology. 2023;36(4):100085.
RkJQdWJsaXNoZXIy MTk4NDMw